F S&P 500
5,206.00 -0.50 (-0.01%) F Dow Jones
38,994.00 -3.00 (-0.01%) F Nasdaq
18,180.00 -15.50 (-0.09%) E-mini Russell 2000 Index Futur
2,072.00 +0.90 (+0.04%) Petróleo
78.62 +0.14 (+0.18%) Oro
2,331.20 0.00 (0.00%)
Aurobindo Pharma Limited (AUROPHARMA.BO)
Aurobindo Pharma Limited
Galaxy, Plot No. 1
22nd-24th Floor Plot No.1, Survey No.83/1 Hyderabad Knowledge City,Raidurg Panmakt
Hyderabad 500032
India
91 40 6672 5000
https://www.aurobindo.com
Sector(es): Healthcare
Industria: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo: 23,451
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Kambam Nityananda Reddy | Vice Chairman & MD | 37.41M | N/D | 1958 |
| Mr. Mettu Madan Mohan Reddy | Whole-Time Director | 52.35M | N/D | 1960 |
| Mr. Santhanam Subramanian | Chief Financial Officer | 21.06M | N/D | 1961 |
| Mr. Sanjeev Indravadan Dani | COO & Head of Formulations | N/D | N/D | 1960 |
| Dr. S. Vijaya Kumar | President of Technical | N/D | N/D | 1966 |
| Mr. Arvind Bothra | Head of Investor Relations & Corporate Communications | N/D | N/D | N/D |
| Mr. B. Adi Reddy | Compliance Officer & Company Secretary | 4.76M | N/D | N/D |
| Mr. G. P. Prasad | Senior Vice President of Global Finance & Operations | N/D | N/D | N/D |
| Dr. Sudhir Bimal Singhi | Head of Global Finance Operations | N/D | N/D | 1969 |
| Dr. A. Rama Mohana Rao | President of Corporate QA | N/D | N/D | 1962 |
Descripción
Aurobindo Pharma Limited engages in manufacturing of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, and internationally. It offers formulation in form of orals, injectables and over-the-counter drugs; and active pharmaceutical ingredients (API) for biosimilars, dermatology, respiratory, vaccines, and peptides, as well as oncology, hormones, and sterile products. The company also provides antiretroviral drugs for the people and children living with HIV; and AuroZymes, a biocatalysts product for use in the pharmaceutical and chemical industries. In addition, it offers AuroSource, a contract services that cover the clinical stage through to manufacturing and management of the entire drug lifecycle in the API space for penicillin's, cephalosporins, and non beta lactams. The company was incorporated in 1986 and is headquartered in Hyderabad, India.
Gestión corporativa
La calificación ISS Governance QuickScore de Aurobindo Pharma Limited a partir del 1 de mayo de 2024 es 1. Las puntuaciones principales son Auditoría: 6; Junta: 2; Derechos del accionista: 1; Compensación: 1.
